Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Transplantation
Volume 2015 (2015), Article ID 286276, 5 pages
http://dx.doi.org/10.1155/2015/286276
Case Report

Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation

1Department of Internal Medicine, California Pacific Medical Center, San Francisco, CA 94115, USA
2Department of Hepatology, California Pacific Medical Center, San Francisco, CA 94115, USA
3Department of Hematology Oncology, California Pacific Medical Center, San Francisco, CA 94115, USA

Received 23 January 2015; Accepted 29 June 2015

Academic Editor: Piero Boraschi

Copyright © 2015 Annie K. Hung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Casadevall, D. Cournoyer, J. Marsh et al., “Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia,” European Journal of Haematology, vol. 73, no. 6, pp. 389–396, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. K.-U. Eckardt and N. Casadevall, “Pure red-cell aplasia due to anti-erythropoietin antibodies,” Nephrology Dialysis Transplantation, vol. 18, no. 5, pp. 865–869, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. I. C. MacDougall, S. D. Roger, A. de Francisco et al., “Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights,” Kidney International, vol. 81, no. 8, pp. 727–732, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Peck-Radosavljevic, M. Wichlas, M. Homoncik-Kraml et al., “Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha,” Gastroenterology, vol. 123, no. 1, pp. 141–151, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. L. De Franceschi, G. Fattovich, F. Turrini et al., “Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage,” Hepatology, vol. 31, no. 4, pp. 997–1004, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. J. G. McHutchison, M. Manns, K. Patel et al., “Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C,” Gastroenterology, vol. 123, no. 4, pp. 1061–1069, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. N. H. Afdhal, D. T. Dieterich, P. J. Pockros et al., “Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study,” Gastroenterology, vol. 126, no. 5, pp. 1302–1311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. P. J. Pockros, M. L. Shiffman, E. R. Schiff et al., “Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy,” Hepatology, vol. 40, no. 6, pp. 1450–1458, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. International Society of Nephrology, “KDIGO clinical practice guidelines for anemia in chronic kidney disease,” Kidney International Supplements, vol. 2, no. 4, pp. 279–335, 2012. View at Google Scholar
  10. J. Rossert, N. Casadevall, and K.-U. Eckardt, “Anti-erythropoietin antibodies and pure red cell aplasia,” Journal of the American Society of Nephrology, vol. 15, no. 2, pp. 398–406, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. C. L. Bennett, D. Cournoyer, K. R. Carson et al., “Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project,” Blood, vol. 106, no. 10, pp. 3343–3347, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Verhelst, J. Rossert, N. Casadevall, A. Krüger, K.-U. Eckardt, and I. C. Macdougall, “Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study,” The Lancet, vol. 363, no. 9423, pp. 1768–1771, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. C. M. Behler, N. A. Terrault, J. E. Etzell, and L. E. Damon, “Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report,” Journal of Medical Case Reports, vol. 3, article 7335, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. C.-S. Chang, S.-L. Yan, H.-Y. Lin, F.-L. Yu, and C.-Y. Tsai, “Pure red cell aplasia caused by pegylated interferon-α-2a plus ribavirin in the treatment of chronic hepatitis C,” World Journal of Gastroenterology, vol. 17, no. 16, pp. 2155–2158, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. T. Stravitz, H. Chung, R. K. Sterling et al., “Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C,” The American Journal of Gastroenterology, vol. 100, no. 6, pp. 1415–1419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. T.-B. Liang, D.-L. Li, J. Yu et al., “Pure red cell aplasia due to parvovirus B19 infection after liver transplantation: a case report and review of the literature,” World Journal of Gastroenterology, vol. 13, no. 13, pp. 2007–2010, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Schecter, J. G. Mears, B. Alobeid, and P. J. Gaglio, “Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus,” Liver Transplantation, vol. 13, no. 11, pp. 1589–1592, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. I. C. Macdougall, A. Roche, J. Rossert, N. Casadevall, P. Francois, and D. M. Kemeny, “Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?” Nephrology Dialysis Transplantation, vol. 19, no. 11, pp. 2901–2905, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Rossert, I. Macdougall, and N. Casadevall, “Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options,” Nephrology Dialysis Transplantation, vol. 20, no. 4, pp. iv23–iv26, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Fishbane, B. Schiller, F. Locatelli et al., “Peginesatide in patients with anemia undergoing hemodialysis,” The New England Journal of Medicine, vol. 368, no. 4, pp. 307–319, 2013. View at Publisher · View at Google Scholar · View at Scopus